Crescendo Bioscience this week released data indicating that its Vectra DA protein biomarker test for rheumatoid arthritis could help identify patients in remission from the disease.
In a poster presented at the European League Against Rheumatism's Annual European Congress of Rheumatology in Berlin, data from a study using the Dutch population-based Leiden Early Arthritis Cohort showed that patients in remission according to their Vectra DA score demonstrated a lower rate (7 percent) of radiographic progression over one year compared to patients in remission according to their DAS28CRP score (20 percent) or their ACR/EULAR Boolean score (17 percent) – two standard measures of RA remission.
The study also showed that patients in DAS28CRP remission who had a high Vectra DA score were 2.3 times more likely to have progressive joint destruction in the next year than those with low Vectra DA scores.
Crescendo's initial commercial product, Vectra DA is an immunoassay-based laboratory-developed test that measures levels of 12 proteins in blood to assess RA activity. Last year, Myriad Genetics made a $25 million debt investment in Crescendo that gives it a three-year option to purchase the company (GWDN 9/9/2011).
Additional data on Vectra DA were also presented this week at the EULAR conference, including posters indicating that the test tracks RA patient response to anti-TNF therapy and that it tracks patient response to treatment with the Jak inhibitor TOFACITINIB.